ZIOPHARM Oncology, Inc.
Head Quarters
One First Avenue Parris Building USWebsite
http://www.ziopharm.comIndustry
BiotechnologyEmployees
36Exchange
NASDAQZIOPHARM Oncology, Inc. is a biopharmaceutical company currently in developmental stage that seeks to acquire, develop and commercialize, on its own or with commercial partners, a diverse portfolio of cancer therapies. It is focused on two clinical stage product candidates: Ad-RTS-IL-12 + veledimex and DC-RTS-IL-12 + veledimex. Ziopharm Oncology was founded on September 9, 2003 and is headquartered in Boston, MA.
Key statistics
| Margins | Stock |
|---|---|
| Revenue per Employee | $0.00 |
| Current Ratio | 5 |
| Gross Margin (%) | 0.00% |
| Net Margin (%) | -2.50% |
| Returns | Stock |
| Sales | $6.00M |
| Sales Growth (% qtr vs. yr ago) | 0.00% |
| Net Income | -$14.00M |
| NI Growth (% qtr vs. yr ago) | 0.00% |
| Price/Sales | 113.24 |
| EPS | -$1.00 |